Are you above the legal age to view this content in your province/state?

Home / Industry News / Positive Results From Trial Of Cannabis Medicine For Insomnia

Positive Results From Trial Of Cannabis Medicine For Insomnia

Positive Results From Trial Of Cannabis Medicine For Insomnia

U.S. , February 21, 2020 (420 INTEL) – It’s looking like Thunderbirds are go for a medical cannabis insomnia product developed by Zelira Therapeutics (ASX:ZLD).

In case you’re wondering who Zelira is, you might recognise it by its previous name – Zelda Therapeutics. The name change came about after a merger with the USA’s Ilera Therapeutics LLC was finalised late last year.

Zelda, err, Zelira has been working on an insomnia product, ZLT-101, for a few years. It first secured regulatory approval to conduct a clinical trial with chronic insomnia patients in Australia back in 2017.

On Wednesday the company announced it had met primary endpoints for its Phase (1b/2a) trial of ZLT-101. It states 23 chronic insomnia patients treated with ZLT-101 demonstrated statistically significant improvement in Insomnia Severity Index (ISI) scores compared to placebo. Additionally, ZLT-101 was well tolerated and no serious adverse events were reported.

This doesn’t mean to say it was free of side- effects. Among the patients who did experience them, the most common was dry mouth, followed by dizziness, headache and “feeling abnormal”. 17 of the 23 patients using ZLT-101 reported side effects, however, 4 participants on the placebo also reported them.

“All adverse events were classified as mild and had either resolved (97.5%) overnight or soon after waking each day or were resolving at the end of the trial,” states Zelira.

The company states lack of serious adverse or persistent mild adverse events is encouraging given those associated with other insomnia therapies.

“The fact that ZLT-101 treatment achieved a statistically significant improvement in ISI scores is very impressive, particularly given the relatively short two-week dosing window,” stated Professor Peter Eastwood, who was the Principal Investigator for the study, and is also the Centre for Sleep Science’s Director. The Centre is based at the University of Western Australia.

While a final report from the clinical study won’t be available until the end of March this year, Zelira Chairman Osagie Imasogie said the company is now in a position to rapidly commercialise ZLT-101 globally – this year.

Chronic insomnia involves difficulty getting asleep, staying asleep or not feeling refreshed after adequate sleep, along with impairment of daytime function for a period of at least 4 weeks.


Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.

Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.

Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.

Investment Value Finders is intended for those 21+ years of age only!

Check Also

Stocks and Founds that are overexposed To Russia And Ukraine

Stock markets worldwide have been in red since Russia began its invasion of Ukraine last …